Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Guardant Health to Participate in Upcoming Investor Conferences

GH

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating virtually in the following investor conferences.

  • 11th Annual SVB Leerink Global Healthcare Conference
    Fireside Chat on Wednesday, February 16 th at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time
  • Citi 2022 Healthcare Conference
    Fireside Chat on Thursday, February 24 th at 11:45 a.m. Pacific Time / 2:45 p.m. Eastern Time
  • Cowen 42nd Annual Health Care Conference
    Fireside Chat on Tuesday, March 8 th at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time

Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today